electroCore (NASDAQ:ECOR – Get Free Report) and Nutriband (NASDAQ:NTRB – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, institutional ownership, valuation, earnings and analyst recommendations.
Profitability
This table compares electroCore and Nutriband’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| electroCore | -43.60% | -1,956.38% | -74.62% |
| Nutriband | -560.89% | -133.22% | -114.00% |
Insider & Institutional Ownership
26.7% of electroCore shares are held by institutional investors. Comparatively, 19.7% of Nutriband shares are held by institutional investors. 13.8% of electroCore shares are held by company insiders. Comparatively, 52.2% of Nutriband shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Volatility and Risk
Analyst Recommendations
This is a breakdown of recent ratings and price targets for electroCore and Nutriband, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| electroCore | 1 | 1 | 1 | 0 | 2.00 |
| Nutriband | 1 | 1 | 0 | 0 | 1.50 |
electroCore presently has a consensus target price of $18.00, indicating a potential upside of 164.71%. Given electroCore’s stronger consensus rating and higher possible upside, equities analysts clearly believe electroCore is more favorable than Nutriband.
Earnings and Valuation
This table compares electroCore and Nutriband”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| electroCore | $32.03 million | 1.72 | -$13.97 million | ($1.65) | -4.12 |
| Nutriband | $2.14 million | 20.66 | -$10.48 million | ($3.07) | -1.18 |
Nutriband has lower revenue, but higher earnings than electroCore. electroCore is trading at a lower price-to-earnings ratio than Nutriband, indicating that it is currently the more affordable of the two stocks.
Summary
electroCore beats Nutriband on 8 of the 14 factors compared between the two stocks.
About electroCore
electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
About Nutriband
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.
